Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2006-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-05-0397PMID 16648580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Target-related affinity profiling: Telik's lead discovery technology.

  2005cited by this paper
• Nordihydroguaiaretic Acid (NDGA) Inhibits the IGF-1 and c-erbB2/HER2/neu Receptors and Suppresses Growth in Breast Cancer Cells

  2005cited by this paper
• In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

  2004cited by this paper
• Solubilizing Excipients in Oral and Injectable Formulations

  2004cited by this paper
• Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

  2004cited by this paper
• Function of the IGF-I Receptor in Breast Cancer

  2004cited by this paper
• Therapeutic Potential of Tyrosine Kinase Inhibitors in Breast Cancer

  2003cited by this paper
• Growth factor receptors in breast cancer: potential for therapeutic intervention.

  2003cited by this paper
• Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics*

  2003cited by this paper
• A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.

  2003cited by this paper
• The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: Biology and therapeutic relevance

  2003cited by this paper
• Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse

  2002cited by this paper
• Chemoproteomics as a basis for post-genomic drug discovery.

  2002cited by this paper
• Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

  2002cited by this paper
• HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.

  2002cited by this paper
• Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.

  2002cited by this paper
• The insulin-like growth factor system as a treatment target in breast cancer.

  2002cited by this paper
• Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase

  2001cited by this paper
• Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival

  2000cited by this paper
• Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

  2000cited by this paper
• From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

  2000cited by this paper
• Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival.

  2000cited by this paper
• Substrate competitive inhibitors of IGF-1 receptor kinase.

  2000cited by this paper
• Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

  2000cited by this paper
• Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

  2000cited by this paper
• Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines.

  2000cited by this paper
• The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.

  2000cited by this paper
• Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism

  1999cited by this paper
• The IGF-I receptor in cancer research.

  1999cited by this paper
• mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells.

  1998cited by this paper
• Antisense phosphorothioate oligodeoxynucleotide down‐regulation of the insulin‐like growth factor I receptor in ovarian cancer cells

  1998cited by this paper
• Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt

  1997cited by this paper
• Decreased muscle insulin receptor kinase correlates with insulin resistance in normoglycemic Pima Indians.

  1997cited by this paper
• Cytochrome P450 species involved in the metabolism of quinoline.

  1996cited by this paper
• Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo.

  1996cited by this paper
• Monoclonal antibody αIR‐3 inhibits non‐small cell lung cancer growth in vitro and in vivo

  1996cited by this paper
• Mechanism of activation of protein kinase B by insulin and IGF‐1.

  1996influential reference
• Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.

  1996cited by this paper
• Microbial metabolism of pyridine, quinoline, acridine, and their derivatives under aerobic and anaerobic conditions.

  1996cited by this paper
• Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid.

  1995cited by this paper
• Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity.

  1995cited by this paper
• Growth factors in breast cancer.

  1995cited by this paper
• Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells.

  1994cited by this paper
• Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant.

  1994cited by this paper
• Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells.

  1994cited by this paper
• Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma.

  1994cited by this paper
• Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors.

  1994cited by this paper
• The Insulin-Like Growth Factor-I Receptor

  1994cited by this paper
• Oncogenes and the strategy of growth factors.

  1994cited by this paper
• Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1.

  1993cited by this paper
• Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

  1992cited by this paper
• Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995).

  1992cited by this paper
• Insulin-like Growth Factors: Molecular and Cellular Aspects

  1991cited by this paper
• Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice.

  1989cited by this paper
• Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.

  1989cited by this paper

• Type II RTKs: Insulin receptor family in GtoPdb v.2025.3

  2025cites this paper
• IGF2-IGF1R signaling inhibition delays the growth of IGF2-high colorectal cancer by modulating MDSCs.

  2024cites this paper
• Diarylureas as Antitumor Agents

  2021cites this paper
• Diarylureas as Antitumor Agents Diarylureas as Antitumor Agents

  2021cites this paper
• Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review

  2021cites this paper
• The Interplay Between Non-coding RNAs and Insulin-Like Growth Factor Signaling in the Pathogenesis of Neoplasia

  2021cites this paper
• Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma

  2020influential citation
• Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

  2020cites this paper
• The Neutrally Charged Diarylurea Compound PQ401 Kills Antibiotic-Resistant and Antibiotic-Tolerant Staphylococcus aureus

  2020cites this paper
• Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion

  2019cites this paper
• Viability and migratory effects of IGF-1R inhibitor, PQ401, on triple negative breast cancer cells

  2019cites this paper
• IGF-1R inhibitor PQ401 inhibits osteosarcoma cell proliferation, migration and colony formation.

  2019cites this paper
• Design, synthesis, and biological evaluation of novel 3‐(thiophen‐2‐ylthio)pyridine derivatives as potential multitarget anticancer agents

  2019cites this paper
• IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients

  2019cites this paper
• Synthesis and In Vitro Antiproliferative Activity of New 1-Phenyl-3-(4-(pyridin-3-yl)phenyl)urea Scaffold-Based Compounds

  2018cites this paper
• Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor

  2018cites this paper
• Identification of di-substituted ureas that prevent growth of trypanosomes through inhibition of translation initiation

  2018cites this paper
• Myeloid p38 MAPK signaling in intestinal homeostasis, inflammation and tumorigenesis = Señalización por la MAPK p38 de células mieloides en la homeostasis, inflamación y tumorogénesis intestinal

  2017cites this paper
• Synthesis and In Vitro Antiproliferative Activity of New -Phenyl-3-(4-(Pyridin-3-Yl)Phenyl)Urea-Scaffold Based Compounds

  2017cites this paper
• The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1

  2017influential citation
• Modeling Polypharmacological Profiles by Affinity Fingerprinting.

  2017cites this paper
• PfIRR Interacts with HrIGF-I and Activates the MAP-kinase and PI3-kinase Signaling Pathways to Regulate Glycogen Metabolism in Pinctada fucata

  2016cites this paper
• PQ401, an IGF-1R inhibitor, induces apoptosis and inhibits growth, proliferation and migration of glioma cells

  2016cites this paper
• Product Data Sheet Chemical Properties Product

  2016cites this paper
• Novel Therapies on the Horizon

  2015cites this paper
• The Effects on Adipocytokines & Bone Metabolic Parameters according to Shoes Heel Hight in Postmenopausal Obese Women

  2014cites this paper
• Haploinsufficiency of the Insulin-Like Growth Factor-1 Receptor Enhances Endothelial Repair and Favorably Modifies Angiogenic Progenitor Cell Phenotype

  2014cites this paper
• Molecular identification of insulin-related peptide receptor and its potential role in regulating development in Pinctada fucata

  2013cites this paper
• Lkb1/Stk11 regulation of mTOR signaling controls the transition of chondrocyte fates and suppresses skeletal tumor formation

  2013cites this paper
• Identification of Novel IGF1R Kinase Inhibitors by Molecular Modeling and High-Throughput Screening

  2013cites this paper
• Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.

  2013cites this paper
• Amadori products promote cellular senescence activating insulin-like growth factor-1 receptor and down-regulating the antioxidant enzyme catalase.

  2013cites this paper
• Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.

  2012cites this paper
• In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.

  2012cites this paper
• Preclinical Development Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH 717454 Is Reversed by IGF2

  2012cites this paper
• Synthesis, anti-inflammatory and antimicrobial evaluation of novel N1-(quinolin-4yl)ethane-1,2-diamine phenyl urea derivatives

  2012cites this paper
• A Novel Cardiomyocyte-enriched MicroRNA, miR-378, Targets Insulin-like Growth Factor 1 Receptor

  2012cites this paper
• Progranulin compensates for blocked IGF‐1 signaling to promote myotube hypertrophy in C2C12 myoblasts via the PI3K/Akt/mTOR pathway

  2012cites this paper
• Insulin-Like Growth Factor Signaling Regulates the Timing of Sensory Cell Differentiation in the Mouse Cochlea

  2011cites this paper
• Influence of energy balance on the somatotrophic axis and matrix metalloproteinase expression in the endometrium of the postpartum dairy cow

  2011cites this paper
• Guide to Receptors and Channels (GRAC), 5th edition

  2011cites this paper
• Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2

  2011cites this paper
• Insulin-like Growth Factor 1-mediated Hyperthermia Involves Anterior Hypothalamic Insulin Receptors*

  2011cites this paper
• The effects of type 1 IGF receptor inhibition in a mouse model of diabetic kidney disease.

  2011cites this paper
• Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells

  2011cites this paper
• Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells.

  2010cites this paper
• The expression and role of hybrid insulin/insulin-like growth factor receptor type 1 in endometrial carcinoma cells.

  2010cites this paper
• Molecular Therapy for Rhabdomyosarcoma

  2010cites this paper
• Characterisation and Mechanism of Bone Marrow Cell-Induced Myocardial Protection

  2010cites this paper
• Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R).

  2010cites this paper
• Nuclear Degradation of Wilms Tumor 1-associating Protein and Survivin Splice Variant Switching Underlie IGF-1-mediated Survival*

  2009cites this paper
• The Insulin-Like Growth Factor Family: Molecular Mechanisms, Redox Regulation, and Clinical Implications

  2009cites this paper
• Diabetes and cancer.

  2009cites this paper
• Chapter 14 Recent Progress in the Development of Small Molecule Inhibitors of Insulin-Like Growth Factor-1 Receptor Kinase

  2009cites this paper
• Drugs targeting insulin-like growth factor 1 receptor

  2009cites this paper
• Bone marrow cell-induced protection of the human myocardium: characterization and mechanism of action.

  2009cites this paper
• Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

  2009cites this paper
• Targeted therapies in breast cancer: established drugs and recent developments.

  2008cites this paper
• Proliferation of breast cancer cells: regulation, mediators, targets for therapy.

  2008cites this paper
• Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients

  2008cites this paper
• Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program

  2008cites this paper
• Rational design of substituted diarylureas: a scaffold for binding to G-quadruplex motifs.

  2008cites this paper
• Synthesis of a novel macrocyclic library: discovery of an IGF-1R inhibitor.

  2008cites this paper
• IGF signaling pathway as a selective target of familial breast cancer therapy.

  2008cites this paper
• Formation of fluorine-18 labeled diaryl ureas--labeled VEGFR-2/PDGFR dual inhibitors as molecular imaging agents for angiogenesis.

  2008cites this paper
• New agents in development for breast cancer

  2007cites this paper
• Apical electrolyte concentration modulates barrier function and tight junction protein localization in bovine mammary epithelium.

  2007cites this paper
• Glucocorticoids induce amiloride-sensitive ion transport by pathways that are tissue-specific

  2007cites this paper
• Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer

  2007cites this paper
• Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I.

  2007cites this paper
• Pediatric oncology.

  2007cites this paper
• Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways

  2007cites this paper
• Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase

  2007cites this paper
• Age-Dependent Impairment of Endothelial Progenitor Cells Is Corrected by Growth Hormone Mediated Increase of Insulin-Like Growth Factor-1

  2007cites this paper
• IGF1R signalling and its inhibition.

  2006cites this paper
• Parallel synthesis of diarylureas and their evaluation as inhibitors of insulin-like growth factor receptor.

  2006cites this paper